Severe stomatitis caused by osimertinib combined with gefitinib: A case report

The 2017 NCCN Guidelines for NSCLC recommend epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as the first‐line treatment for patients with gene‐sensitive mutations of pulmonary adenocarcinoma. The TKI combination can effectively inhibit the gene mutations caused by the drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ya‐ning, Li, Li, Zhang, Peng, Zuo, Yan, Lei, Yu, Bai, Jun, Cao, Lu, Guo, Zhen‐Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843833/
https://www.ncbi.nlm.nih.gov/pubmed/35223006
http://dx.doi.org/10.1002/ccr3.5396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843833/
https://www.ncbi.nlm.nih.gov/pubmed/35223006
http://dx.doi.org/10.1002/ccr3.5396

Ejemplares similares